Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells

Probukolün Lösemi, Multipl Miyeloma, Lenfoma ve Fibroblast Hücre Hatlarının Proliferasyonu Üzerindeki Etkileri

Aslı KOÇ, Arzu Zeynep KARABAY, Ali YAPRAK, Zeliha BÜYÜKBİNGÖL, Fügen AKTAN

Abstract

Objectives: Probucol is a bisphenol antioxidant with antiinflammatory, antilipidemic and antidiabetic effect. Development and progression of cancer is closely related to chronic inflammation and oxidative stress. Agents that target these processes have been shown to modulate cancer cell proliferation. In this regard, the effect of probucol on proliferation of different cancer cell lines was investigated. Materials and Methods: Different concentrations of probucol solutions were prepared and applied to the following cancer cell lines: K562S (imatinib sensitive) and K562R (imatinib resistant) chronic myeloid leukemia (CML) cells; U937 histiocytic lymphoma cells; HL60 acute myeloid leukemia cells; U266, H929, and RPMI8226 multiple myeloma cells; and L929 fibroblast cells. Cell viability was conducted by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide assay. Results: Significant toxicity was not exhibited due to probucol treatment (0.1-10 µM) in K562S and K562R CML cells, U937 histiocytic lymphoma cells, HL60 acute myeloid leukemia cells, U266 multiple myeloma cells, and L929 fibroblast cells. However, probucol treatment significantly inhibited the viability of H929 and RPMI8226 multiple myeloma cells at the concentration of 0.5-10 µM and 5-10 µM, respectively. Conclusion: Probucol treatment slightly inhibited the viability of other cancer cell lines, but significantly inhibited the viability of H929 and RPMI8226 multiple myeloma cells. However, its effect was not potent, since a 50% reduction in cell viability could not be achieved at the concentrations of probucol treatment administered. Key words: Probucol, chronic myeloid leukemia, multiple myeloma, histiocytic lymphoma, acute myeloid leukemia

Özet

Amaç: Probukol, antiinflamatuvar, antilipidemik ve antidiyabetik aktivitelere sahip bisfenol bir antioksidandır. Kanser gelişimi ve ilerlemesi kronik inflamasyon ve oksidatif stres ile yakından ilişkilidir ve bu süreçleri hedefleyen ajanların kanser hücre proliferasyonunu modüle ettikleri gösterilmiştir. Bu bağlamda, bu çalışmada, probukolün farklı kanser hücre hatlarının proliferasyonu üzerindeki etkileri araştırılmıştır. Gereç ve Yöntemler: Probukolün farklı konsantrasyonlarda hazırlanan çözeltileri kullanılarak K562S (imatinib duyarılı), K562R (imatinib dirençli) kronik miyeloid lösemi (KML), U937 histiositik lenfoma, HL60 akut miyeloid lösemi, U266 multipl miyeloma ve L929 fibroblast hücre hatlarında hücre canlılığı 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium testi ile belirlenmiştir. Bulgular: Probukol uygulaması (0,1 µM-10 µM), K562S, K562R KML, U937 histositik lenfoma, HL60 akut miyeloid lösemi, U266, H929, RPMI8226 multipl miyelom ve L929 fibroblast hücre hatlarında anlamlı bir etki göstermemiştir. Diğer taraftan, probukol uygulaması, H929 ve RPMI8226 hücre serilerinin canlılığını sırasıyla 0,5-10 µM and 5-10 µM konsantrasyon aralığında anlamlı olarak azaltmıştır (p